Corcept Therapeutics Inc
relacorilant
platinum-resistant ovarian cancer
Resolved
188days ago
Phase 3 readout · ~ Dec 31, 2025 estimated
What's at stake
Phase 3 trial results for relacorilant in platinum-resistant ovarian cancer are due ~ Dec 31, 2025. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 15h ago
“Findings were first presented at ASCO 2025 (American Society of Clinical Oncology) with simultaneous publication in The Lancet.”